insights_auto
Kwa nini NOVOBN imeongezeka kwa 5.67%?
Fahamu zaidichevron_right
NOVOBN:BMV
Novo Nordisk A/S
MX$ 764.50
arrow_upward
+5.67%(+41.00) Siku 1
16 Okt, 14:00:00 GMT -6 · MXN
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya NOVOBN...
Fungua
MX$ 728.00
Juu
MX$ 764.50
Chini
MX$ 728.00
Mtaji wa soko
132.00B
Wastani wa kiasi cha mauzo
386.00
Kiasi cha mauzo ya hisa
21.00
Juu kwa wiki 52
MX$ 1,149.99
Chini kwa wiki 52
MX$ 630.00
Idadi ya wafanyakazi
elfu 67
Fungua
MX$ 728.00
Juu
MX$ 764.50
Chini
MX$ 728.00
Mtaji wa soko
132.00B
Wastani wa kiasi cha mauzo
386.00
Kiasi cha mauzo ya hisa
21.00
Juu kwa wiki 52
MX$ 1,149.99
Chini kwa wiki 52
MX$ 630.00
Idadi ya wafanyakazi
elfu 67
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Simply Wall Street
·
saa 2 zilizopita
Novo Nordisk (NVO) Stock May Be Undervalued As Buybacks Continue
The Motley Fool
·
siku 1 iliyopita
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Yahoo Finance
·
siku 1 iliyopita
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
TradingKey
·
siku 2 zilizopita
Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know
Wasifu
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Kuhusu Novo Nordisk A/S
Afisa Mkuu Mtendaji (CEO)Maziar Mike Doustdar
Wafanyakazielfu 66.7
Lilianzishwa1923
Makao makuuBagsværd, Capital Region of Denmark, Denmaki
Sekta-
Tovutinovonordisk.com